#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Within this study , we used real-time CGM ( rtCGM ) in combination with a serial analysis of blood and exhaled breath in a highly standardized setting in pediatric T1DM patients and healthy controls over a time course of nine hours .
3-1	15-21	Within	_	_	_	_
3-2	22-26	this	abstract[3]	new[3]	coref	18-25[142_3]
3-3	27-32	study	abstract[3]	new[3]	_	_
3-4	33-34	,	_	_	_	_
3-5	35-37	we	person	acc	ana	4-1
3-6	38-42	used	_	_	_	_
3-7	43-52	real-time	abstract[5]	new[5]	appos	3-10[0_5]
3-8	53-56	CGM	abstract[5]	new[5]	_	_
3-9	57-58	(	_	_	_	_
3-10	59-64	rtCGM	abstract	giv	_	_
3-11	65-66	)	_	_	_	_
3-12	67-69	in	_	_	_	_
3-13	70-81	combination	abstract[7]	new[7]	_	_
3-14	82-86	with	abstract[7]	new[7]	_	_
3-15	87-88	a	abstract[7]|abstract[8]	new[7]|new[8]	coref	6-2[46_8]
3-16	89-95	serial	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-17	96-104	analysis	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-18	105-107	of	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-19	108-113	blood	abstract[7]|abstract[8]|substance	new[7]|new[8]|new	coref	4-16
3-20	114-117	and	_	_	_	_
3-21	118-125	exhaled	abstract|abstract|abstract	new|new|new	coref|coref|coref|none|none|none|coref|coref|coref|none|none|none|coref|coref|coref|none|none|none	6-14[49_0]|12-9[89_0]|12-9[90_0]|3-21[0_49]|3-21[0_89]|3-21[0_90]|6-14[49_0]|12-9[89_0]|12-9[90_0]|3-21[0_49]|3-21[0_89]|3-21[0_90]|6-14[49_0]|12-9[89_0]|12-9[90_0]|3-21[0_49]|3-21[0_89]|3-21[0_90]
3-22	126-132	breath	abstract	new	coref	4-8
3-23	133-135	in	_	_	_	_
3-24	136-137	a	abstract[11]	new[11]	_	_
3-25	138-144	highly	abstract[11]	new[11]	_	_
3-26	145-157	standardized	abstract[11]	new[11]	_	_
3-27	158-165	setting	abstract[11]	new[11]	_	_
3-28	166-168	in	abstract[11]	new[11]	_	_
3-29	169-178	pediatric	abstract[11]|person[13]|abstract[14]	new[11]|new[13]|new[14]	coref|coref|coref|coref	12-16[93_13]|22-25[179_14]|12-16[93_13]|22-25[179_14]
3-30	179-183	T1DM	abstract[11]|abstract|person[13]|abstract[14]	new[11]|new|new[13]|new[14]	coref	9-5
3-31	184-192	patients	abstract[11]|person[13]|abstract[14]	new[11]|new[13]|new[14]	_	_
3-32	193-196	and	abstract[11]|abstract[14]	new[11]|new[14]	_	_
3-33	197-204	healthy	abstract[11]|abstract[14]|event[15]	new[11]|new[14]|new[15]	coref	12-20[0_15]
3-34	205-213	controls	abstract[11]|abstract[14]|event[15]	new[11]|new[14]|new[15]	_	_
3-35	214-218	over	abstract[11]|abstract[14]|event[15]	new[11]|new[14]|new[15]	_	_
3-36	219-220	a	abstract[11]|abstract[14]|event[15]|time[17]	new[11]|new[14]|new[15]|new[17]	_	_
3-37	221-225	time	abstract[11]|abstract[14]|event[15]|abstract|time[17]	new[11]|new[14]|new[15]|new|new[17]	_	_
3-38	226-232	course	abstract[11]|abstract[14]|event[15]|time[17]	new[11]|new[14]|new[15]|new[17]	_	_
3-39	233-235	of	abstract[11]|abstract[14]|event[15]|time[17]	new[11]|new[14]|new[15]|new[17]	_	_
3-40	236-240	nine	abstract[11]|abstract[14]|event[15]|time[17]|time[18]	new[11]|new[14]|new[15]|new[17]|new[18]	_	_
3-41	241-246	hours	abstract[11]|abstract[14]|event[15]|time[17]|time[18]	new[11]|new[14]|new[15]|new[17]|new[18]	_	_
3-42	247-248	.	_	_	_	_

#Text=We accumulated more than 4000 measurements of breath VOCs and interstitial glucose and almost 1000 blood samples from 44 participants .
4-1	249-251	We	person	giv	ana	6-11
4-2	252-263	accumulated	_	_	_	_
4-3	264-268	more	abstract[20]	new[20]	_	_
4-4	269-273	than	abstract[20]	new[20]	_	_
4-5	274-278	4000	abstract[20]	new[20]	_	_
4-6	279-291	measurements	abstract[20]	new[20]	_	_
4-7	292-294	of	abstract[20]	new[20]	_	_
4-8	295-301	breath	abstract[20]|abstract|object[22]	new[20]|giv|new[22]	coref|coref|coref|coref	5-25|8-19[68_22]|5-25|8-19[68_22]
4-9	302-306	VOCs	abstract[20]|object[22]	new[20]|new[22]	_	_
4-10	307-310	and	abstract[20]	new[20]	_	_
4-11	311-323	interstitial	abstract[20]|substance[23]	new[20]|new[23]	coref	7-7[0_23]
4-12	324-331	glucose	abstract[20]|substance[23]	new[20]|new[23]	_	_
4-13	332-335	and	abstract[20]	new[20]	_	_
4-14	336-342	almost	abstract[20]|object[25]	new[20]|new[25]	_	_
4-15	343-347	1000	abstract[20]|object[25]	new[20]|new[25]	_	_
4-16	348-353	blood	abstract[20]|substance|object[25]	new[20]|giv|new[25]	coref	5-38
4-17	354-361	samples	abstract[20]|object[25]	new[20]|new[25]	_	_
4-18	362-366	from	abstract[20]|object[25]	new[20]|new[25]	_	_
4-19	367-369	44	abstract[20]|object[25]|person[26]	new[20]|new[25]|new[26]	_	_
4-20	370-382	participants	abstract[20]|object[25]|person[26]	new[20]|new[25]|new[26]	_	_
4-21	383-384	.	_	_	_	_

#Text=Standardization with respect to physical activity , the interval between meals , the type and amount of nutrients , and the restriction to alveolar breath sampling allows the generation of highly comparable diurnal profiles of breath and blood born parameters relative to the metabolic state .
5-1	385-400	Standardization	abstract[27]	new[27]	_	_
5-2	401-405	with	abstract[27]	new[27]	_	_
5-3	406-413	respect	abstract[27]|abstract[28]	new[27]|new[28]	coref	22-34[181_28]
5-4	414-416	to	abstract[27]|abstract[28]	new[27]|new[28]	_	_
5-5	417-425	physical	abstract[27]|abstract[28]|abstract[29]	new[27]|new[28]|new[29]	_	_
5-6	426-434	activity	abstract[27]|abstract[28]|abstract[29]	new[27]|new[28]|new[29]	_	_
5-7	435-436	,	_	_	_	_
5-8	437-440	the	time[30]	new[30]	coref	13-18[105_30]
5-9	441-449	interval	time[30]	new[30]	_	_
5-10	450-457	between	time[30]	new[30]	_	_
5-11	458-463	meals	time[30]|object	new[30]|new	coref	25-30
5-12	464-465	,	time[30]	new[30]	_	_
5-13	466-469	the	time[30]|abstract[32]	new[30]|new[32]	_	_
5-14	470-474	type	time[30]|abstract[32]	new[30]|new[32]	_	_
5-15	475-478	and	time[30]|abstract[32]	new[30]|new[32]	_	_
5-16	479-485	amount	time[30]|abstract[32]|abstract	new[30]|new[32]|new	coref	11-17[85_0]
5-17	486-488	of	time[30]|abstract[32]	new[30]|new[32]	_	_
5-18	489-498	nutrients	time[30]|abstract[32]|substance	new[30]|new[32]|new	_	_
5-19	499-500	,	_	_	_	_
5-20	501-504	and	_	_	_	_
5-21	505-508	the	abstract[35]	new[35]	_	_
5-22	509-520	restriction	abstract[35]	new[35]	_	_
5-23	521-523	to	abstract[35]	new[35]	_	_
5-24	524-532	alveolar	abstract[35]|object[37]	new[35]|new[37]	coref	8-11[67_37]
5-25	533-539	breath	abstract[35]|abstract|object[37]	new[35]|giv|new[37]	coref	5-36
5-26	540-548	sampling	abstract[35]|object[37]	new[35]|new[37]	_	_
5-27	549-555	allows	_	_	_	_
5-28	556-559	the	abstract[38]	new[38]	_	_
5-29	560-570	generation	abstract[38]	new[38]	_	_
5-30	571-573	of	abstract[38]	new[38]	_	_
5-31	574-580	highly	abstract[38]|object[39]	new[38]|new[39]	_	_
5-32	581-591	comparable	abstract[38]|object[39]	new[38]|new[39]	_	_
5-33	592-599	diurnal	abstract[38]|object[39]	new[38]|new[39]	_	_
5-34	600-608	profiles	abstract[38]|object[39]	new[38]|new[39]	_	_
5-35	609-611	of	abstract[38]|object[39]	new[38]|new[39]	_	_
5-36	612-618	breath	abstract[38]|object[39]|object	new[38]|new[39]|giv	coref	6-3
5-37	619-622	and	abstract[38]|object[39]	new[38]|new[39]	_	_
5-38	623-628	blood	abstract[38]|object[39]|substance	new[38]|new[39]|giv	coref	8-12
5-39	629-633	born	abstract[38]|object[39]|abstract[42]	new[38]|new[39]|new[42]	_	_
5-40	634-644	parameters	abstract[38]|object[39]|abstract[42]	new[38]|new[39]|new[42]	_	_
5-41	645-653	relative	abstract[38]|object[39]|abstract[42]	new[38]|new[39]|new[42]	_	_
5-42	654-656	to	_	_	_	_
5-43	657-660	the	abstract[44]	new[44]	_	_
5-44	661-670	metabolic	person|abstract[44]	new|new[44]	coref	21-17
5-45	671-676	state	abstract[44]	new[44]	_	_
5-46	677-678	.	_	_	_	_

#Text=For real-time breath analysis , a PTR-ToF-MS was used and we focused on the exhalation of ethanol , acetone , isopropanol , dimethyl sulfide , isoprene , pentanal , and limonene .
6-1	679-682	For	_	_	_	_
6-2	683-692	real-time	abstract[46]	giv[46]	_	_
6-3	693-699	breath	object|abstract[46]	giv|giv[46]	coref	9-15
6-4	700-708	analysis	abstract[46]	giv[46]	_	_
6-5	709-710	,	_	_	_	_
6-6	711-712	a	object[47]	new[47]	_	_
6-7	713-723	PTR-ToF-MS	object[47]	new[47]	_	_
6-8	724-727	was	_	_	_	_
6-9	728-732	used	_	_	_	_
6-10	733-736	and	_	_	_	_
6-11	737-739	we	person	giv	ana	8-3
6-12	740-747	focused	_	_	_	_
6-13	748-750	on	_	_	_	_
6-14	751-754	the	abstract[49]	new[49]	_	_
6-15	755-765	exhalation	abstract[49]	new[49]	_	_
6-16	766-768	of	abstract[49]	new[49]	_	_
6-17	769-776	ethanol	abstract[49]|substance	new[49]|new	_	_
6-18	777-778	,	abstract[49]	new[49]	_	_
6-19	779-786	acetone	abstract[49]|substance	new[49]|new	coref	9-7
6-20	787-788	,	abstract[49]	new[49]	_	_
6-21	789-800	isopropanol	abstract[49]|substance	new[49]|new	coref	19-18
6-22	801-802	,	abstract[49]	new[49]	_	_
6-23	803-811	dimethyl	abstract[49]|substance[53]	new[49]|new[53]	_	_
6-24	812-819	sulfide	abstract[49]|substance[53]	new[49]|new[53]	_	_
6-25	820-821	,	abstract[49]	new[49]	_	_
6-26	822-830	isoprene	abstract[49]|substance	new[49]|new	_	_
6-27	831-832	,	abstract[49]	new[49]	_	_
6-28	833-841	pentanal	abstract[49]|substance	new[49]|new	_	_
6-29	842-843	,	abstract[49]	new[49]	_	_
6-30	844-847	and	abstract[49]	new[49]	_	_
6-31	848-856	limonene	abstract[49]|substance	new[49]|new	_	_
6-32	857-858	.	_	_	_	_

#Text=These compounds have been linked to glucose metabolism and/or to T1DM-related comorbidities including oxidative stress .
7-1	859-864	These	substance[57]	new[57]	_	_
7-2	865-874	compounds	substance[57]	new[57]	_	_
7-3	875-879	have	_	_	_	_
7-4	880-884	been	_	_	_	_
7-5	885-891	linked	_	_	_	_
7-6	892-894	to	_	_	_	_
7-7	895-902	glucose	substance	giv	coref	13-7
7-8	903-913	metabolism	abstract	new	_	_
7-9	914-920	and/or	_	_	_	_
7-10	921-923	to	_	_	_	_
7-11	924-936	T1DM-related	abstract[60]	new[60]	_	_
7-12	937-950	comorbidities	abstract[60]	new[60]	_	_
7-13	951-960	including	abstract[60]	new[60]	_	_
7-14	961-970	oxidative	abstract[60]|abstract|abstract[62]	new[60]|new|new[62]	_	_
7-15	971-977	stress	abstract[60]|abstract[62]	new[60]|new[62]	_	_
7-16	978-979	.	_	_	_	_

#Text=Thus , we investigated the fade of classical markers via repetitive blood sampling and looked in parallel for the VOCs mentioned above .
8-1	980-984	Thus	_	_	_	_
8-2	985-986	,	_	_	_	_
8-3	987-989	we	person	giv	ana	12-5
8-4	990-1002	investigated	_	_	_	_
8-5	1003-1006	the	abstract[64]	new[64]	_	_
8-6	1007-1011	fade	abstract[64]	new[64]	_	_
8-7	1012-1014	of	abstract[64]	new[64]	_	_
8-8	1015-1024	classical	abstract[64]|abstract[65]	new[64]|new[65]	_	_
8-9	1025-1032	markers	abstract[64]|abstract[65]	new[64]|new[65]	_	_
8-10	1033-1036	via	abstract[64]|abstract[65]	new[64]|new[65]	_	_
8-11	1037-1047	repetitive	abstract[64]|abstract[65]|object[67]	new[64]|new[65]|giv[67]	coref	13-25[109_67]
8-12	1048-1053	blood	abstract[64]|abstract[65]|substance|object[67]	new[64]|new[65]|giv|giv[67]	coref	12-27
8-13	1054-1062	sampling	abstract[64]|abstract[65]|object[67]	new[64]|new[65]|giv[67]	_	_
8-14	1063-1066	and	_	_	_	_
8-15	1067-1073	looked	_	_	_	_
8-16	1074-1076	in	_	_	_	_
8-17	1077-1085	parallel	_	_	_	_
8-18	1086-1089	for	_	_	_	_
8-19	1090-1093	the	object[68]	giv[68]	_	_
8-20	1094-1098	VOCs	object[68]	giv[68]	_	_
8-21	1099-1108	mentioned	_	_	_	_
8-22	1109-1114	above	_	_	_	_
8-23	1115-1116	.	_	_	_	_

#Text=In the case of T1DM , acetone is certainly the most prominent VOC in breath and has previously been investigated under various conditions .
9-1	1117-1119	In	_	_	_	_
9-2	1120-1123	the	abstract[69]	new[69]	_	_
9-3	1124-1128	case	abstract[69]	new[69]	_	_
9-4	1129-1131	of	abstract[69]	new[69]	_	_
9-5	1132-1136	T1DM	abstract[69]|abstract	new[69]|giv	coref	12-16
9-6	1137-1138	,	_	_	_	_
9-7	1139-1146	acetone	abstract	giv	coref	9-9[72_0]
9-8	1147-1149	is	_	_	_	_
9-9	1150-1159	certainly	abstract[72]	giv[72]	coref	10-1[0_72]
9-10	1160-1163	the	abstract[72]	giv[72]	_	_
9-11	1164-1168	most	abstract[72]	giv[72]	_	_
9-12	1169-1178	prominent	abstract[72]	giv[72]	_	_
9-13	1179-1182	VOC	abstract[72]	giv[72]	_	_
9-14	1183-1185	in	abstract[72]	giv[72]	_	_
9-15	1186-1192	breath	abstract[72]|abstract	giv[72]|giv	coref	13-25
9-16	1193-1196	and	_	_	_	_
9-17	1197-1200	has	_	_	_	_
9-18	1201-1211	previously	_	_	_	_
9-19	1212-1216	been	_	_	_	_
9-20	1217-1229	investigated	_	_	_	_
9-21	1230-1235	under	_	_	_	_
9-22	1236-1243	various	abstract[74]	new[74]	coref	18-12[137_74]
9-23	1244-1254	conditions	abstract[74]	new[74]	_	_
9-24	1255-1256	.	_	_	_	_

#Text=Acetone originates from enzymatic or non-enzymatic decarboxylation of acetoacetate via Acetyl-CoA which is derived from pyruvate .
10-1	1257-1264	Acetone	substance	giv	coref	12-14[91_0]
10-2	1265-1275	originates	_	_	_	_
10-3	1276-1280	from	_	_	_	_
10-4	1281-1290	enzymatic	abstract	new	ana	11-12
10-5	1291-1293	or	_	_	_	_
10-6	1294-1307	non-enzymatic	substance[77]	new[77]	_	_
10-7	1308-1323	decarboxylation	substance[77]	new[77]	_	_
10-8	1324-1326	of	substance[77]	new[77]	_	_
10-9	1327-1339	acetoacetate	substance[77]|substance[78]	new[77]|new[78]	_	_
10-10	1340-1343	via	substance[77]|substance[78]	new[77]|new[78]	_	_
10-11	1344-1354	Acetyl-CoA	substance[77]|substance[78]|substance	new[77]|new[78]|new	_	_
10-12	1355-1360	which	_	_	_	_
10-13	1361-1363	is	_	_	_	_
10-14	1364-1371	derived	_	_	_	_
10-15	1372-1376	from	_	_	_	_
10-16	1377-1385	pyruvate	substance	new	_	_
10-17	1386-1387	.	_	_	_	_

#Text=Since the latter can originate from both glycolysis and lipolysis , it is impossible to differentiate the amount from either pathway .
11-1	1388-1393	Since	_	_	_	_
11-2	1394-1397	the	_	_	_	_
11-3	1398-1404	latter	_	_	_	_
11-4	1405-1408	can	_	_	_	_
11-5	1409-1418	originate	_	_	_	_
11-6	1419-1423	from	_	_	_	_
11-7	1424-1428	both	substance[81]	new[81]	coref	14-28[117_81]
11-8	1429-1439	glycolysis	substance[81]	new[81]	_	_
11-9	1440-1443	and	_	_	_	_
11-10	1444-1453	lipolysis	substance	new	coref	14-26
11-11	1454-1455	,	_	_	_	_
11-12	1456-1458	it	abstract	giv	_	_
11-13	1459-1461	is	_	_	_	_
11-14	1462-1472	impossible	_	_	_	_
11-15	1473-1475	to	person[84]	new[84]	_	_
11-16	1476-1489	differentiate	person[84]	new[84]	_	_
11-17	1490-1493	the	person[84]|abstract[85]	new[84]|giv[85]	_	_
11-18	1494-1500	amount	person[84]|abstract[85]	new[84]|giv[85]	_	_
11-19	1501-1505	from	person[84]|abstract[85]	new[84]|giv[85]	_	_
11-20	1506-1512	either	person[84]|abstract[85]|place[86]	new[84]|giv[85]|new[86]	coref	21-5[162_86]
11-21	1513-1520	pathway	person[84]|abstract[85]|place[86]	new[84]|giv[85]|new[86]	_	_
11-22	1521-1522	.	_	_	_	_

#Text=Regardless of this , we and others noted the significantly elevated exhalation of acetone in T1DM patients compared to controls , as well as the elevated blood levels in T1DM patients .
12-1	1523-1533	Regardless	_	_	_	_
12-2	1534-1536	of	_	_	_	_
12-3	1537-1541	this	_	_	_	_
12-4	1542-1543	,	_	_	_	_
12-5	1544-1546	we	person	giv	ana	18-25
12-6	1547-1550	and	_	_	_	_
12-7	1551-1557	others	person	new	_	_
12-8	1558-1563	noted	_	_	_	_
12-9	1564-1567	the	abstract[89]|abstract[90]	new[89]|new[90]	_	_
12-10	1568-1581	significantly	abstract[89]|abstract[90]	new[89]|new[90]	_	_
12-11	1582-1590	elevated	abstract[89]|abstract[90]	new[89]|new[90]	_	_
12-12	1591-1601	exhalation	abstract[89]|abstract[90]	new[89]|new[90]	_	_
12-13	1602-1604	of	abstract[89]|abstract[90]	new[89]|new[90]	_	_
12-14	1605-1612	acetone	abstract[89]|abstract[90]|substance[91]	new[89]|new[90]|giv[91]	coref	13-9[0_91]
12-15	1613-1615	in	abstract[89]|abstract[90]|substance[91]	new[89]|new[90]|giv[91]	_	_
12-16	1616-1620	T1DM	abstract[89]|abstract[90]|substance[91]|abstract|person[93]	new[89]|new[90]|giv[91]|giv|giv[93]	coref|coref|coref|coref	12-30|12-30[98_93]|12-30|12-30[98_93]
12-17	1621-1629	patients	abstract[89]|abstract[90]|substance[91]|person[93]	new[89]|new[90]|giv[91]|giv[93]	_	_
12-18	1630-1638	compared	abstract[90]	new[90]	_	_
12-19	1639-1641	to	abstract[90]	new[90]	_	_
12-20	1642-1650	controls	abstract[90]|event	new[90]|giv	coref	22-28[180_0]
12-21	1651-1652	,	abstract[90]	new[90]	_	_
12-22	1653-1655	as	abstract[90]	new[90]	_	_
12-23	1656-1660	well	abstract[90]	new[90]	_	_
12-24	1661-1663	as	abstract[90]	new[90]	_	_
12-25	1664-1667	the	abstract[90]|abstract[96]	new[90]|new[96]	coref	24-12[203_96]
12-26	1668-1676	elevated	abstract[90]|abstract[96]	new[90]|new[96]	_	_
12-27	1677-1682	blood	abstract[90]|substance|abstract[96]	new[90]|giv|new[96]	coref	16-9
12-28	1683-1689	levels	abstract[90]|abstract[96]	new[90]|new[96]	_	_
12-29	1690-1692	in	abstract[90]|abstract[96]	new[90]|new[96]	_	_
12-30	1693-1697	T1DM	abstract[90]|abstract[96]|abstract|person[98]	new[90]|new[96]|giv|giv[98]	coref|coref|coref|coref	13-12|13-12[103_98]|13-12|13-12[103_98]
12-31	1698-1706	patients	abstract[90]|abstract[96]|person[98]	new[90]|new[96]|giv[98]	_	_
12-32	1707-1708	.	_	_	_	_

#Text=However , although the concentrations of glucose and acetone correlated in T1DM patients , the time and/or the interval between food intake , and breath sampling appears to be an important confounder .
13-1	1709-1716	However	_	_	_	_
13-2	1717-1718	,	_	_	_	_
13-3	1719-1727	although	_	_	_	_
13-4	1728-1731	the	animal[99]	new[99]	coref	25-26[223_99]
13-5	1732-1746	concentrations	animal[99]	new[99]	_	_
13-6	1747-1749	of	animal[99]	new[99]	_	_
13-7	1750-1757	glucose	animal[99]|substance	new[99]|giv	coref	16-9[129_0]
13-8	1758-1761	and	animal[99]	new[99]	_	_
13-9	1762-1769	acetone	animal[99]|substance	new[99]|giv	coref	14-33
13-10	1770-1780	correlated	_	_	_	_
13-11	1781-1783	in	_	_	_	_
13-12	1784-1788	T1DM	event|person[103]	giv|giv[103]	coref|coref|coref|coref	20-4|20-4[152_103]|20-4|20-4[152_103]
13-13	1789-1797	patients	person[103]	giv[103]	_	_
13-14	1798-1799	,	_	_	_	_
13-15	1800-1803	the	time[104]	new[104]	coref	20-23[157_104]
13-16	1804-1808	time	time[104]	new[104]	_	_
13-17	1809-1815	and/or	time[104]	new[104]	_	_
13-18	1816-1819	the	time[104]|time[105]	new[104]|giv[105]	_	_
13-19	1820-1828	interval	time[104]|time[105]	new[104]|giv[105]	_	_
13-20	1829-1836	between	time[104]|time[105]	new[104]|giv[105]	_	_
13-21	1837-1841	food	time[104]|time[105]|substance|event[107]	new[104]|giv[105]|new|new[107]	coref|coref	15-5[121_107]|15-5[121_107]
13-22	1842-1848	intake	time[104]|time[105]|event[107]	new[104]|giv[105]|new[107]	_	_
13-23	1849-1850	,	_	_	_	_
13-24	1851-1854	and	_	_	_	_
13-25	1855-1861	breath	abstract|object[109]	giv|giv[109]	coref|coref	29-6|29-6
13-26	1862-1870	sampling	object[109]	giv[109]	_	_
13-27	1871-1878	appears	_	_	_	_
13-28	1879-1881	to	_	_	_	_
13-29	1882-1884	be	_	_	_	_
13-30	1885-1887	an	abstract[110]	new[110]	_	_
13-31	1888-1897	important	abstract[110]	new[110]	_	_
13-32	1898-1908	confounder	abstract[110]	new[110]	_	_
13-33	1909-1910	.	_	_	_	_

#Text=In the morning , when ketogenesis is high due to overnight fasting , correlations were low , most probably due to an additive effect of lipolysis and glycolysis on the formation of acetone .
14-1	1911-1913	In	_	_	_	_
14-2	1914-1917	the	time[111]	new[111]	_	_
14-3	1918-1925	morning	time[111]	new[111]	_	_
14-4	1926-1927	,	_	_	_	_
14-5	1928-1932	when	_	_	_	_
14-6	1933-1944	ketogenesis	substance	new	_	_
14-7	1945-1947	is	_	_	_	_
14-8	1948-1952	high	_	_	_	_
14-9	1953-1956	due	_	_	_	_
14-10	1957-1959	to	_	_	_	_
14-11	1960-1969	overnight	time[113]	new[113]	_	_
14-12	1970-1977	fasting	time[113]	new[113]	_	_
14-13	1978-1979	,	_	_	_	_
14-14	1980-1992	correlations	abstract	new	_	_
14-15	1993-1997	were	_	_	_	_
14-16	1998-2001	low	_	_	_	_
14-17	2002-2003	,	_	_	_	_
14-18	2004-2008	most	_	_	_	_
14-19	2009-2017	probably	_	_	_	_
14-20	2018-2021	due	_	_	_	_
14-21	2022-2024	to	_	_	_	_
14-22	2025-2027	an	abstract[115]	new[115]	_	_
14-23	2028-2036	additive	abstract[115]	new[115]	_	_
14-24	2037-2043	effect	abstract[115]	new[115]	_	_
14-25	2044-2046	of	abstract[115]	new[115]	_	_
14-26	2047-2056	lipolysis	abstract[115]|substance	new[115]|giv	coref	15-14
14-27	2057-2060	and	abstract[115]	new[115]	_	_
14-28	2061-2071	glycolysis	abstract[115]|substance[117]	new[115]|giv[117]	_	_
14-29	2072-2074	on	abstract[115]|substance[117]	new[115]|giv[117]	_	_
14-30	2075-2078	the	abstract[115]|substance[117]|event[118]	new[115]|giv[117]|new[118]	_	_
14-31	2079-2088	formation	abstract[115]|substance[117]|event[118]	new[115]|giv[117]|new[118]	_	_
14-32	2089-2091	of	abstract[115]|substance[117]|event[118]	new[115]|giv[117]|new[118]	_	_
14-33	2092-2099	acetone	abstract[115]|substance[117]|event[118]|substance	new[115]|giv[117]|new[118]|giv	coref	16-7
14-34	2100-2101	.	_	_	_	_

#Text=Correlation improved markedly after a moderate intake of carbohydrates and insulin-related inhibition of lipolysis .
15-1	2102-2113	Correlation	abstract	new	coref	16-5[126_0]
15-2	2114-2122	improved	_	_	_	_
15-3	2123-2131	markedly	_	_	_	_
15-4	2132-2137	after	_	_	_	_
15-5	2138-2139	a	event[121]	giv[121]	coref	30-25[274_121]
15-6	2140-2148	moderate	event[121]	giv[121]	_	_
15-7	2149-2155	intake	event[121]	giv[121]	_	_
15-8	2156-2158	of	event[121]	giv[121]	_	_
15-9	2159-2172	carbohydrates	event[121]|substance	giv[121]|new	coref	29-36
15-10	2173-2176	and	event[121]	giv[121]	_	_
15-11	2177-2192	insulin-related	event[121]|abstract[123]	giv[121]|new[123]	_	_
15-12	2193-2203	inhibition	event[121]|abstract[123]	giv[121]|new[123]	_	_
15-13	2204-2206	of	event[121]|abstract[123]	giv[121]|new[123]	_	_
15-14	2207-2216	lipolysis	event[121]|abstract[123]|substance	giv[121]|new[123]|giv	_	_
15-15	2217-2218	.	_	_	_	_

#Text=In the afternoon , correlation between acetone and blood glucose remained low .
16-1	2219-2221	In	_	_	_	_
16-2	2222-2225	the	time[125]	new[125]	_	_
16-3	2226-2235	afternoon	time[125]	new[125]	_	_
16-4	2236-2237	,	_	_	_	_
16-5	2238-2249	correlation	abstract[126]	giv[126]	ana	17-1[0_126]
16-6	2250-2257	between	abstract[126]	giv[126]	_	_
16-7	2258-2265	acetone	abstract[126]|substance	giv[126]|giv	coref	18-6[134_0]
16-8	2266-2269	and	abstract[126]	giv[126]	_	_
16-9	2270-2275	blood	abstract[126]|substance|substance[129]	giv[126]|giv|giv[129]	coref|coref|coref|coref	18-8|18-8[136_129]|18-8|18-8[136_129]
16-10	2276-2283	glucose	abstract[126]|substance[129]	giv[126]|giv[129]	_	_
16-11	2284-2292	remained	_	_	_	_
16-12	2293-2296	low	_	_	_	_
16-13	2297-2298	.	_	_	_	_

#Text=This was most probably due to postprandial hyperglycemia .
17-1	2299-2303	This	abstract	giv	coref	18-3[133_0]
17-2	2304-2307	was	_	_	_	_
17-3	2308-2312	most	_	_	_	_
17-4	2313-2321	probably	_	_	_	_
17-5	2322-2325	due	_	_	_	_
17-6	2326-2328	to	_	_	_	_
17-7	2329-2341	postprandial	abstract|abstract[132]	new|new[132]	coref|coref	26-19[231_132]|26-19[231_132]
17-8	2342-2355	hyperglycemia	abstract[132]	new[132]	_	_
17-9	2356-2357	.	_	_	_	_

#Text=Thus , a correlation of acetone with blood glucose is difficult even under healthy conditions and the time-resolved calculation of the correlation coefficients in our study strengthen this observation .
18-1	2358-2362	Thus	_	_	_	_
18-2	2363-2364	,	_	_	_	_
18-3	2365-2366	a	abstract[133]	giv[133]	coref	18-22[0_133]
18-4	2367-2378	correlation	abstract[133]	giv[133]	_	_
18-5	2379-2381	of	abstract[133]	giv[133]	_	_
18-6	2382-2389	acetone	abstract[133]|substance[134]	giv[133]|giv[134]	coref	19-16[149_134]
18-7	2390-2394	with	abstract[133]|substance[134]	giv[133]|giv[134]	_	_
18-8	2395-2400	blood	abstract[133]|substance[134]|substance|substance[136]	giv[133]|giv[134]|giv|giv[136]	coref|coref	24-12|24-12
18-9	2401-2408	glucose	abstract[133]|substance[134]|substance[136]	giv[133]|giv[134]|giv[136]	_	_
18-10	2409-2411	is	_	_	_	_
18-11	2412-2421	difficult	_	_	_	_
18-12	2422-2426	even	abstract[137]	giv[137]	coref	24-2[198_137]
18-13	2427-2432	under	abstract[137]	giv[137]	_	_
18-14	2433-2440	healthy	abstract[137]	giv[137]	_	_
18-15	2441-2451	conditions	abstract[137]	giv[137]	_	_
18-16	2452-2455	and	_	_	_	_
18-17	2456-2459	the	abstract[138]	new[138]	_	_
18-18	2460-2473	time-resolved	abstract[138]	new[138]	_	_
18-19	2474-2485	calculation	abstract[138]	new[138]	_	_
18-20	2486-2488	of	abstract[138]	new[138]	_	_
18-21	2489-2492	the	abstract[138]|abstract[140]	new[138]|new[140]	coref	20-26[159_140]
18-22	2493-2504	correlation	abstract[138]|abstract|abstract[140]	new[138]|giv|new[140]	coref	20-26
18-23	2505-2517	coefficients	abstract[138]|abstract[140]	new[138]|new[140]	_	_
18-24	2518-2520	in	abstract[138]|abstract[140]	new[138]|new[140]	_	_
18-25	2521-2524	our	abstract[138]|abstract[140]|person|abstract[142]	new[138]|new[140]|giv|giv[142]	_	_
18-26	2525-2530	study	abstract[138]|abstract[140]|abstract[142]	new[138]|new[140]|giv[142]	_	_
18-27	2531-2541	strengthen	_	_	_	_
18-28	2542-2546	this	abstract[143]	new[143]	_	_
18-29	2547-2558	observation	abstract[143]	new[143]	_	_
18-30	2559-2560	.	_	_	_	_

#Text=Furthermore , the impact of hepatic alcohol dehydrogenase , i. e. , the reduction of acetone to isopropanol , has to be considered .
19-1	2561-2572	Furthermore	_	_	_	_
19-2	2573-2574	,	_	_	_	_
19-3	2575-2578	the	abstract[144]	new[144]	_	_
19-4	2579-2585	impact	abstract[144]	new[144]	_	_
19-5	2586-2588	of	abstract[144]	new[144]	_	_
19-6	2589-2596	hepatic	abstract[144]|substance|abstract[147]	new[144]|new|new[147]	_	_
19-7	2597-2604	alcohol	abstract[144]|substance|abstract[147]	new[144]|new|new[147]	_	_
19-8	2605-2618	dehydrogenase	abstract[144]|abstract[147]	new[144]|new[147]	_	_
19-9	2619-2620	,	abstract[144]	new[144]	_	_
19-10	2621-2623	i.	abstract[144]	new[144]	_	_
19-11	2624-2626	e.	abstract[144]	new[144]	_	_
19-12	2627-2628	,	abstract[144]	new[144]	_	_
19-13	2629-2632	the	abstract[144]|event[148]	new[144]|new[148]	_	_
19-14	2633-2642	reduction	abstract[144]|event[148]	new[144]|new[148]	_	_
19-15	2643-2645	of	abstract[144]|event[148]	new[144]|new[148]	_	_
19-16	2646-2653	acetone	abstract[144]|event[148]|substance[149]	new[144]|new[148]|giv[149]	coref	20-33[0_149]
19-17	2654-2656	to	abstract[144]|event[148]|substance[149]	new[144]|new[148]|giv[149]	_	_
19-18	2657-2668	isopropanol	abstract[144]|event[148]|substance[149]|substance	new[144]|new[148]|giv[149]|giv	coref	20-7[153_0]
19-19	2669-2670	,	_	_	_	_
19-20	2671-2674	has	_	_	_	_
19-21	2675-2677	to	_	_	_	_
19-22	2678-2680	be	_	_	_	_
19-23	2681-2691	considered	_	_	_	_
19-24	2692-2693	.	_	_	_	_

#Text=In fact , T1DM patients exhaled significantly more isopropanol than their healthy peers and both , the diurnal profile as well as the time resolved correlation coefficients , closely resembled that of acetone .
20-1	2694-2696	In	_	_	_	_
20-2	2697-2701	fact	_	_	_	_
20-3	2702-2703	,	_	_	_	_
20-4	2704-2708	T1DM	abstract|person[152]	giv|giv[152]	ana|coref|ana|coref	20-11[0_152]|21-8|20-11[0_152]|21-8
20-5	2709-2717	patients	person[152]	giv[152]	_	_
20-6	2718-2725	exhaled	_	_	_	_
20-7	2726-2739	significantly	substance[153]	giv[153]	_	_
20-8	2740-2744	more	substance[153]	giv[153]	_	_
20-9	2745-2756	isopropanol	substance[153]	giv[153]	_	_
20-10	2757-2761	than	substance[153]	giv[153]	_	_
20-11	2762-2767	their	substance[153]|person|person[155]	giv[153]|giv|new[155]	coref|coref	21-8[164_0]|21-8[164_0]
20-12	2768-2775	healthy	substance[153]|person[155]	giv[153]|new[155]	_	_
20-13	2776-2781	peers	substance[153]|person[155]	giv[153]|new[155]	_	_
20-14	2782-2785	and	substance[153]	giv[153]	_	_
20-15	2786-2790	both	substance[153]	giv[153]	_	_
20-16	2791-2792	,	substance[153]	giv[153]	_	_
20-17	2793-2796	the	substance[153]|abstract[156]	giv[153]|new[156]	_	_
20-18	2797-2804	diurnal	substance[153]|abstract[156]	giv[153]|new[156]	_	_
20-19	2805-2812	profile	substance[153]|abstract[156]	giv[153]|new[156]	_	_
20-20	2813-2815	as	_	_	_	_
20-21	2816-2820	well	_	_	_	_
20-22	2821-2823	as	_	_	_	_
20-23	2824-2827	the	time[157]	giv[157]	coref	24-28[209_157]
20-24	2828-2832	time	time[157]	giv[157]	_	_
20-25	2833-2841	resolved	_	_	_	_
20-26	2842-2853	correlation	abstract|abstract[159]	giv|giv[159]	coref|coref	29-1[252_0]|29-1[252_0]
20-27	2854-2866	coefficients	abstract[159]	giv[159]	_	_
20-28	2867-2868	,	_	_	_	_
20-29	2869-2876	closely	_	_	_	_
20-30	2877-2886	resembled	_	_	_	_
20-31	2887-2891	that	_	_	_	_
20-32	2892-2894	of	_	_	_	_
20-33	2895-2902	acetone	substance	giv	coref	21-13
20-34	2903-2904	.	_	_	_	_

#Text=Thus , activation of this pathway in T1DM patients may attribute to acetone elimination and indicate metabolic adaptation .
21-1	2905-2909	Thus	_	_	_	_
21-2	2910-2911	,	_	_	_	_
21-3	2912-2922	activation	abstract[161]	new[161]	_	_
21-4	2923-2925	of	abstract[161]	new[161]	_	_
21-5	2926-2930	this	abstract[161]|place[162]	new[161]|giv[162]	ana	23-1[0_162]
21-6	2931-2938	pathway	abstract[161]|place[162]	new[161]|giv[162]	_	_
21-7	2939-2941	in	abstract[161]|place[162]	new[161]|giv[162]	_	_
21-8	2942-2946	T1DM	abstract[161]|place[162]|abstract|person[164]	new[161]|giv[162]|giv|giv[164]	coref|coref|coref|coref	22-25|22-25[178_164]|22-25|22-25[178_164]
21-9	2947-2955	patients	abstract[161]|place[162]|person[164]	new[161]|giv[162]|giv[164]	_	_
21-10	2956-2959	may	_	_	_	_
21-11	2960-2969	attribute	_	_	_	_
21-12	2970-2972	to	_	_	_	_
21-13	2973-2980	acetone	substance|abstract[166]	giv|new[166]	_	_
21-14	2981-2992	elimination	abstract[166]	new[166]	_	_
21-15	2993-2996	and	_	_	_	_
21-16	2997-3005	indicate	_	_	_	_
21-17	3006-3015	metabolic	person|abstract[168]	giv|new[168]	_	_
21-18	3016-3026	adaptation	abstract[168]	new[168]	_	_
21-19	3027-3028	.	_	_	_	_

#Text=The shape of the normalized diurnal profiles of glucose , insulin , glucagon , lipids , leptin , and slepR are fairly comparable in T1DM patients and healthy controls , but differ with respect to slope and inter-individual variability , i. e. , changes over time are faster in controls while inter-individual variability is much greater in T1DM patients .
22-1	3029-3032	The	abstract[169]	new[169]	_	_
22-2	3033-3038	shape	abstract[169]	new[169]	_	_
22-3	3039-3041	of	abstract[169]	new[169]	_	_
22-4	3042-3045	the	abstract[169]|abstract[170]	new[169]|new[170]	coref	29-13[258_170]
22-5	3046-3056	normalized	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-6	3057-3064	diurnal	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-7	3065-3073	profiles	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-8	3074-3076	of	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-9	3077-3084	glucose	abstract[169]|abstract[170]|substance	new[169]|new[170]|new	coref	23-29
22-10	3085-3086	,	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-11	3087-3094	insulin	abstract[169]|abstract[170]|substance	new[169]|new[170]|new	coref	23-17
22-12	3095-3096	,	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-13	3097-3105	glucagon	abstract[169]|abstract[170]|substance	new[169]|new[170]|new	coref	23-31
22-14	3106-3107	,	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-15	3108-3114	lipids	abstract[169]|abstract[170]|substance	new[169]|new[170]|new	_	_
22-16	3115-3116	,	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-17	3117-3123	leptin	abstract[169]|abstract[170]|substance	new[169]|new[170]|new	_	_
22-18	3124-3125	,	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-19	3126-3129	and	abstract[169]|abstract[170]	new[169]|new[170]	_	_
22-20	3130-3135	slepR	abstract[169]|abstract[170]|substance	new[169]|new[170]|new	_	_
22-21	3136-3139	are	_	_	_	_
22-22	3140-3146	fairly	_	_	_	_
22-23	3147-3157	comparable	_	_	_	_
22-24	3158-3160	in	_	_	_	_
22-25	3161-3165	T1DM	abstract|person[178]|abstract[179]	giv|giv[178]|giv[179]	coref|coref|coref|coref|coref|coref|coref|coref|coref	22-58|22-58[188_178]|31-29[288_179]|22-58|22-58[188_178]|31-29[288_179]|22-58|22-58[188_178]|31-29[288_179]
22-26	3166-3174	patients	person[178]|abstract[179]	giv[178]|giv[179]	_	_
22-27	3175-3178	and	abstract[179]	giv[179]	_	_
22-28	3179-3186	healthy	abstract[179]|event[180]	giv[179]|giv[180]	coref	22-50[0_180]
22-29	3187-3195	controls	abstract[179]|event[180]	giv[179]|giv[180]	_	_
22-30	3196-3197	,	_	_	_	_
22-31	3198-3201	but	_	_	_	_
22-32	3202-3208	differ	_	_	_	_
22-33	3209-3213	with	_	_	_	_
22-34	3214-3221	respect	abstract[181]	giv[181]	coref	31-23[284_181]
22-35	3222-3224	to	abstract[181]	giv[181]	_	_
22-36	3225-3230	slope	abstract[181]|abstract	giv[181]|new	_	_
22-37	3231-3234	and	abstract[181]	giv[181]	_	_
22-38	3235-3251	inter-individual	abstract[181]|abstract[183]	giv[181]|new[183]	coref	22-52[186_183]
22-39	3252-3263	variability	abstract[181]|abstract[183]	giv[181]|new[183]	_	_
22-40	3264-3265	,	abstract[181]	giv[181]	_	_
22-41	3266-3268	i.	abstract[181]	giv[181]	_	_
22-42	3269-3271	e.	abstract[181]	giv[181]	_	_
22-43	3272-3273	,	_	_	_	_
22-44	3274-3281	changes	abstract[184]	new[184]	_	_
22-45	3282-3286	over	abstract[184]	new[184]	_	_
22-46	3287-3291	time	abstract[184]	new[184]	_	_
22-47	3292-3295	are	_	_	_	_
22-48	3296-3302	faster	_	_	_	_
22-49	3303-3305	in	_	_	_	_
22-50	3306-3314	controls	event	giv	coref	31-32
22-51	3315-3320	while	_	_	_	_
22-52	3321-3337	inter-individual	abstract[186]	giv[186]	_	_
22-53	3338-3349	variability	abstract[186]	giv[186]	_	_
22-54	3350-3352	is	_	_	_	_
22-55	3353-3357	much	_	_	_	_
22-56	3358-3365	greater	_	_	_	_
22-57	3366-3368	in	_	_	_	_
22-58	3369-3373	T1DM	abstract|person[188]	giv|giv[188]	coref|coref|coref|coref	26-5|26-5[227_188]|26-5|26-5[227_188]
22-59	3374-3382	patients	person[188]	giv[188]	_	_
22-60	3383-3384	.	_	_	_	_

#Text=This might , at least in part , be due to the limited abilities of pharmaceutical insulin preparations to mimic the physiological interplay between insulin-induced cellular uptake of glucose and glucagon secretion .
23-1	3385-3389	This	place	giv	_	_
23-2	3390-3395	might	_	_	_	_
23-3	3396-3397	,	_	_	_	_
23-4	3398-3400	at	_	_	_	_
23-5	3401-3406	least	_	_	_	_
23-6	3407-3409	in	_	_	_	_
23-7	3410-3414	part	_	_	_	_
23-8	3415-3416	,	_	_	_	_
23-9	3417-3419	be	_	_	_	_
23-10	3420-3423	due	_	_	_	_
23-11	3424-3426	to	_	_	_	_
23-12	3427-3430	the	abstract[190]	new[190]	_	_
23-13	3431-3438	limited	abstract[190]	new[190]	_	_
23-14	3439-3448	abilities	abstract[190]	new[190]	_	_
23-15	3449-3451	of	abstract[190]	new[190]	_	_
23-16	3452-3466	pharmaceutical	abstract[190]|object[192]	new[190]|new[192]	_	_
23-17	3467-3474	insulin	abstract[190]|object|object[192]	new[190]|giv|new[192]	coref	24-5
23-18	3475-3487	preparations	abstract[190]|object[192]	new[190]|new[192]	_	_
23-19	3488-3490	to	_	_	_	_
23-20	3491-3496	mimic	_	_	_	_
23-21	3497-3500	the	abstract[193]	new[193]	_	_
23-22	3501-3514	physiological	abstract[193]	new[193]	_	_
23-23	3515-3524	interplay	abstract[193]	new[193]	_	_
23-24	3525-3532	between	abstract[193]	new[193]	_	_
23-25	3533-3548	insulin-induced	abstract[193]|abstract[194]	new[193]|new[194]	coref	24-18[205_194]
23-26	3549-3557	cellular	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-27	3558-3564	uptake	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-28	3565-3567	of	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-29	3568-3575	glucose	abstract[193]|abstract[194]|substance	new[193]|new[194]|giv	coref	24-13
23-30	3576-3579	and	abstract[193]|abstract[194]	new[193]|new[194]	_	_
23-31	3580-3588	glucagon	abstract[193]|abstract[194]|abstract|substance[197]	new[193]|new[194]|giv|new[197]	coref|coref|coref|coref	24-25|24-24[208_197]|24-25|24-24[208_197]
23-32	3589-3598	secretion	abstract[193]|abstract[194]|substance[197]	new[193]|new[194]|new[197]	_	_
23-33	3599-3600	.	_	_	_	_

#Text=Under physiological conditions , insulin is secreted in response to increasing blood glucose levels and by inducing cellular glucose uptake and inhibition of pancreatic glucagon secretion at the same time it contributes to maintenance of glucose homeostasis .
24-1	3601-3606	Under	_	_	_	_
24-2	3607-3620	physiological	abstract[198]	giv[198]	_	_
24-3	3621-3631	conditions	abstract[198]	giv[198]	_	_
24-4	3632-3633	,	_	_	_	_
24-5	3634-3641	insulin	substance	giv	coref	25-26
24-6	3642-3644	is	_	_	_	_
24-7	3645-3653	secreted	_	_	_	_
24-8	3654-3656	in	_	_	_	_
24-9	3657-3665	response	abstract	new	_	_
24-10	3666-3668	to	_	_	_	_
24-11	3669-3679	increasing	_	_	_	_
24-12	3680-3685	blood	substance|abstract[203]	giv|giv[203]	coref|coref|coref|coref	25-10|28-17[242_203]|25-10|28-17[242_203]
24-13	3686-3693	glucose	substance|abstract[203]	giv|giv[203]	coref	24-19
24-14	3694-3700	levels	abstract[203]	giv[203]	_	_
24-15	3701-3704	and	_	_	_	_
24-16	3705-3707	by	_	_	_	_
24-17	3708-3716	inducing	_	_	_	_
24-18	3717-3725	cellular	abstract[205]	giv[205]	_	_
24-19	3726-3733	glucose	substance|abstract[205]	giv|giv[205]	coref	24-36
24-20	3734-3740	uptake	abstract[205]	giv[205]	_	_
24-21	3741-3744	and	_	_	_	_
24-22	3745-3755	inhibition	event[206]	new[206]	_	_
24-23	3756-3758	of	event[206]	new[206]	_	_
24-24	3759-3769	pancreatic	event[206]|substance[208]	new[206]|giv[208]	ana	24-31[0_208]
24-25	3770-3778	glucagon	event[206]|abstract|substance[208]	new[206]|giv|giv[208]	coref	25-7
24-26	3779-3788	secretion	event[206]|substance[208]	new[206]|giv[208]	_	_
24-27	3789-3791	at	event[206]|substance[208]	new[206]|giv[208]	_	_
24-28	3792-3795	the	event[206]|substance[208]|time[209]	new[206]|giv[208]|giv[209]	coref	29-26[261_209]
24-29	3796-3800	same	event[206]|substance[208]|time[209]	new[206]|giv[208]|giv[209]	_	_
24-30	3801-3805	time	event[206]|substance[208]|time[209]	new[206]|giv[208]|giv[209]	_	_
24-31	3806-3808	it	substance	giv	_	_
24-32	3809-3820	contributes	_	_	_	_
24-33	3821-3823	to	_	_	_	_
24-34	3824-3835	maintenance	abstract[211]	new[211]	_	_
24-35	3836-3838	of	abstract[211]	new[211]	_	_
24-36	3839-3846	glucose	abstract[211]|substance|abstract[213]	new[211]|giv|new[213]	coref|coref	25-18|25-18
24-37	3847-3858	homeostasis	abstract[211]|abstract[213]	new[211]|new[213]	_	_
24-38	3859-3860	.	_	_	_	_

#Text=Thus , in healthy individuals , glucagon concentration in blood remains constant as long as the blood glucose concentration stays within the normal range and insulin concentrations peak after meals .
25-1	3861-3865	Thus	_	_	_	_
25-2	3866-3867	,	_	_	_	_
25-3	3868-3870	in	_	_	_	_
25-4	3871-3878	healthy	person[214]	new[214]	_	_
25-5	3879-3890	individuals	person[214]	new[214]	_	_
25-6	3891-3892	,	_	_	_	_
25-7	3893-3901	glucagon	abstract|abstract[216]	giv|new[216]	coref|coref|coref|coref	25-16[220_216]|26-7|25-16[220_216]|26-7
25-8	3902-3915	concentration	abstract[216]	new[216]	_	_
25-9	3916-3918	in	abstract[216]	new[216]	_	_
25-10	3919-3924	blood	abstract[216]|substance	new[216]|giv	coref	25-17
25-11	3925-3932	remains	_	_	_	_
25-12	3933-3941	constant	_	_	_	_
25-13	3942-3944	as	_	_	_	_
25-14	3945-3949	long	_	_	_	_
25-15	3950-3952	as	_	_	_	_
25-16	3953-3956	the	abstract[220]	giv[220]	coref	29-14[0_220]
25-17	3957-3962	blood	substance|abstract[220]	giv|giv[220]	_	_
25-18	3963-3970	glucose	substance|abstract[220]	giv|giv[220]	_	_
25-19	3971-3984	concentration	abstract[220]	giv[220]	_	_
25-20	3985-3990	stays	_	_	_	_
25-21	3991-3997	within	_	_	_	_
25-22	3998-4001	the	abstract[221]	new[221]	_	_
25-23	4002-4008	normal	abstract[221]	new[221]	_	_
25-24	4009-4014	range	abstract[221]	new[221]	_	_
25-25	4015-4018	and	_	_	_	_
25-26	4019-4026	insulin	substance|animal[223]	giv|giv[223]	coref|coref|coref|coref	26-7[229_223]|28-30|26-7[229_223]|28-30
25-27	4027-4041	concentrations	animal[223]	giv[223]	_	_
25-28	4042-4046	peak	_	_	_	_
25-29	4047-4052	after	_	_	_	_
25-30	4053-4058	meals	object	giv	coref	26-12[230_0]
25-31	4059-4060	.	_	_	_	_

#Text=In contrast , in T1DM patients glucagon concentrations remain partially elevated even after meals and most likely aggravate postprandial hyperglycemia .
26-1	4061-4063	In	_	_	_	_
26-2	4064-4072	contrast	abstract	new	_	_
26-3	4073-4074	,	_	_	_	_
26-4	4075-4077	in	_	_	_	_
26-5	4078-4082	T1DM	abstract|person[227]	giv|giv[227]	coref|coref|coref|coref	28-49|28-48[251_227]|28-49|28-48[251_227]
26-6	4083-4091	patients	person[227]	giv[227]	_	_
26-7	4092-4100	glucagon	substance|animal[229]	giv|giv[229]	coref|coref	32-16[293_229]|32-16[293_229]
26-8	4101-4115	concentrations	animal[229]	giv[229]	_	_
26-9	4116-4122	remain	_	_	_	_
26-10	4123-4132	partially	_	_	_	_
26-11	4133-4141	elevated	_	_	_	_
26-12	4142-4146	even	object[230]	giv[230]	_	_
26-13	4147-4152	after	object[230]	giv[230]	_	_
26-14	4153-4158	meals	object[230]	giv[230]	_	_
26-15	4159-4162	and	_	_	_	_
26-16	4163-4167	most	_	_	_	_
26-17	4168-4174	likely	_	_	_	_
26-18	4175-4184	aggravate	_	_	_	_
26-19	4185-4197	postprandial	abstract[231]	giv[231]	coref	31-14[282_231]
26-20	4198-4211	hyperglycemia	abstract[231]	giv[231]	_	_
26-21	4212-4213	.	_	_	_	_

#Text=The latter , especially in concert with dyslipidemia is considered as a relevant contributor to the overall increased risk for the development of cardiovascular disease .
27-1	4214-4217	The	_	_	_	_
27-2	4218-4224	latter	_	_	_	_
27-3	4225-4226	,	_	_	_	_
27-4	4227-4237	especially	event[232]	new[232]	_	_
27-5	4238-4240	in	event[232]	new[232]	_	_
27-6	4241-4248	concert	event[232]	new[232]	_	_
27-7	4249-4253	with	event[232]	new[232]	_	_
27-8	4254-4266	dyslipidemia	event[232]|abstract	new[232]|new	_	_
27-9	4267-4269	is	_	_	_	_
27-10	4270-4280	considered	_	_	_	_
27-11	4281-4283	as	_	_	_	_
27-12	4284-4285	a	_	_	_	_
27-13	4286-4294	relevant	_	_	_	_
27-14	4295-4306	contributor	_	_	_	_
27-15	4307-4309	to	_	_	_	_
27-16	4310-4313	the	abstract[234]	new[234]	_	_
27-17	4314-4321	overall	abstract[234]	new[234]	_	_
27-18	4322-4331	increased	abstract[234]	new[234]	_	_
27-19	4332-4336	risk	abstract[234]	new[234]	_	_
27-20	4337-4340	for	abstract[234]	new[234]	_	_
27-21	4341-4344	the	abstract[234]|event[235]	new[234]|new[235]	_	_
27-22	4345-4356	development	abstract[234]|event[235]	new[234]|new[235]	_	_
27-23	4357-4359	of	abstract[234]|event[235]	new[234]|new[235]	_	_
27-24	4360-4374	cardiovascular	abstract[234]|event[235]|abstract|abstract[237]	new[234]|new[235]|new|new[237]	_	_
27-25	4375-4382	disease	abstract[234]|event[235]|abstract[237]	new[234]|new[235]|new[237]	_	_
27-26	4383-4384	.	_	_	_	_

#Text=On the one hand , poor glycemic control is likely to result in elevated cholesterol and triglyceride levels , on the other hand , peripheral hyperinsulinemia secondary to subcutaneous insulin administration contribute to qualitative abnormalities of lipid metabolism as well and this has recently been shown in young T1DM patients .
28-1	4385-4387	On	_	_	_	_
28-2	4388-4391	the	_	_	_	_
28-3	4392-4395	one	_	_	_	_
28-4	4396-4400	hand	_	_	_	_
28-5	4401-4402	,	_	_	_	_
28-6	4403-4407	poor	abstract[239]	new[239]	_	_
28-7	4408-4416	glycemic	abstract|abstract[239]	new|new[239]	_	_
28-8	4417-4424	control	abstract[239]	new[239]	_	_
28-9	4425-4427	is	_	_	_	_
28-10	4428-4434	likely	_	_	_	_
28-11	4435-4437	to	_	_	_	_
28-12	4438-4444	result	_	_	_	_
28-13	4445-4447	in	_	_	_	_
28-14	4448-4456	elevated	substance[240]	new[240]	_	_
28-15	4457-4468	cholesterol	substance[240]	new[240]	_	_
28-16	4469-4472	and	_	_	_	_
28-17	4473-4485	triglyceride	abstract|abstract[242]	new|giv[242]	_	_
28-18	4486-4492	levels	abstract[242]	giv[242]	_	_
28-19	4493-4494	,	_	_	_	_
28-20	4495-4497	on	_	_	_	_
28-21	4498-4501	the	_	_	_	_
28-22	4502-4507	other	_	_	_	_
28-23	4508-4512	hand	_	_	_	_
28-24	4513-4514	,	_	_	_	_
28-25	4515-4525	peripheral	abstract[243]	new[243]	_	_
28-26	4526-4542	hyperinsulinemia	abstract[243]	new[243]	_	_
28-27	4543-4552	secondary	abstract[243]	new[243]	_	_
28-28	4553-4555	to	_	_	_	_
28-29	4556-4568	subcutaneous	event[245]	new[245]	ana	28-42[0_245]
28-30	4569-4576	insulin	substance|event[245]	giv|new[245]	_	_
28-31	4577-4591	administration	event[245]	new[245]	_	_
28-32	4592-4602	contribute	_	_	_	_
28-33	4603-4605	to	_	_	_	_
28-34	4606-4617	qualitative	event[246]	new[246]	_	_
28-35	4618-4631	abnormalities	event[246]	new[246]	_	_
28-36	4632-4634	of	event[246]	new[246]	_	_
28-37	4635-4640	lipid	event[246]|object|abstract[248]	new[246]|new|new[248]	_	_
28-38	4641-4651	metabolism	event[246]|abstract[248]	new[246]|new[248]	_	_
28-39	4652-4654	as	_	_	_	_
28-40	4655-4659	well	_	_	_	_
28-41	4660-4663	and	_	_	_	_
28-42	4664-4668	this	event	giv	_	_
28-43	4669-4672	has	_	_	_	_
28-44	4673-4681	recently	_	_	_	_
28-45	4682-4686	been	_	_	_	_
28-46	4687-4692	shown	_	_	_	_
28-47	4693-4695	in	_	_	_	_
28-48	4696-4701	young	person[251]	giv[251]	coref	31-29[287_251]
28-49	4702-4706	T1DM	abstract|person[251]	giv|giv[251]	coref	31-29
28-50	4707-4715	patients	person[251]	giv[251]	_	_
28-51	4716-4717	.	_	_	_	_

#Text=Albeit no clear correlation between breath ethanol and serum triglycerides exists , the concentration profiles were quite similar , especially in the second half of the examination period , i. e. , after challenge with carbohydrates ( pasta ) at lunch .
29-1	4718-4724	Albeit	abstract[252]	giv[252]	_	_
29-2	4725-4727	no	abstract[252]	giv[252]	_	_
29-3	4728-4733	clear	abstract[252]	giv[252]	_	_
29-4	4734-4745	correlation	abstract[252]	giv[252]	_	_
29-5	4746-4753	between	abstract[252]	giv[252]	_	_
29-6	4754-4760	breath	abstract[252]|abstract|substance[254]	giv[252]|giv|new[254]	coref|coref|coref|coref	30-1[266_254]|30-19|30-1[266_254]|30-19
29-7	4761-4768	ethanol	abstract[252]|substance[254]	giv[252]|new[254]	_	_
29-8	4769-4772	and	abstract[252]	giv[252]	_	_
29-9	4773-4778	serum	abstract[252]|abstract|substance[256]	giv[252]|new|new[256]	_	_
29-10	4779-4792	triglycerides	abstract[252]|substance[256]	giv[252]|new[256]	_	_
29-11	4793-4799	exists	_	_	_	_
29-12	4800-4801	,	_	_	_	_
29-13	4802-4805	the	abstract[258]	giv[258]	_	_
29-14	4806-4819	concentration	abstract|abstract[258]	giv|giv[258]	_	_
29-15	4820-4828	profiles	abstract[258]	giv[258]	_	_
29-16	4829-4833	were	_	_	_	_
29-17	4834-4839	quite	_	_	_	_
29-18	4840-4847	similar	_	_	_	_
29-19	4848-4849	,	_	_	_	_
29-20	4850-4860	especially	time[259]	new[259]	_	_
29-21	4861-4863	in	time[259]	new[259]	_	_
29-22	4864-4867	the	time[259]	new[259]	_	_
29-23	4868-4874	second	time[259]	new[259]	_	_
29-24	4875-4879	half	time[259]	new[259]	_	_
29-25	4880-4882	of	time[259]	new[259]	_	_
29-26	4883-4886	the	time[259]|time[261]	new[259]|giv[261]	_	_
29-27	4887-4898	examination	time[259]|event|time[261]	new[259]|new|giv[261]	_	_
29-28	4899-4905	period	time[259]|time[261]	new[259]|giv[261]	_	_
29-29	4906-4907	,	_	_	_	_
29-30	4908-4910	i.	_	_	_	_
29-31	4911-4913	e.	_	_	_	_
29-32	4914-4915	,	_	_	_	_
29-33	4916-4921	after	_	_	_	_
29-34	4922-4931	challenge	event[262]	new[262]	_	_
29-35	4932-4936	with	event[262]	new[262]	_	_
29-36	4937-4950	carbohydrates	event[262]|substance	new[262]|giv	appos	29-38
29-37	4951-4952	(	_	_	_	_
29-38	4953-4958	pasta	substance	giv	coref	30-14
29-39	4959-4960	)	_	_	_	_
29-40	4961-4963	at	_	_	_	_
29-41	4964-4969	lunch	event	new	coref	31-6
29-42	4970-4971	.	_	_	_	_

#Text=Endogenous ethanol is supposed to originate from intestinal bacterial activity via fermentation of carbohydrates , i. e. , breath ethanol increase is due to the intake with subsequent digestion of carbohydrates and the intestinal microbiota .
30-1	4972-4982	Endogenous	substance[266]	giv[266]	coref	30-20[0_266]
30-2	4983-4990	ethanol	substance[266]	giv[266]	_	_
30-3	4991-4993	is	_	_	_	_
30-4	4994-5002	supposed	_	_	_	_
30-5	5003-5005	to	_	_	_	_
30-6	5006-5015	originate	_	_	_	_
30-7	5016-5020	from	_	_	_	_
30-8	5021-5031	intestinal	abstract[268]	new[268]	_	_
30-9	5032-5041	bacterial	substance|abstract[268]	new|new[268]	_	_
30-10	5042-5050	activity	abstract[268]	new[268]	_	_
30-11	5051-5054	via	abstract[268]	new[268]	_	_
30-12	5055-5067	fermentation	abstract[268]|substance[269]	new[268]|new[269]	_	_
30-13	5068-5070	of	abstract[268]|substance[269]	new[268]|new[269]	_	_
30-14	5071-5084	carbohydrates	abstract[268]|substance[269]|substance	new[268]|new[269]|giv	coref	30-31
30-15	5085-5086	,	abstract[268]|substance[269]	new[268]|new[269]	_	_
30-16	5087-5089	i.	abstract[268]|substance[269]	new[268]|new[269]	_	_
30-17	5090-5092	e.	abstract[268]|substance[269]	new[268]|new[269]	_	_
30-18	5093-5094	,	abstract[268]|substance[269]	new[268]|new[269]	_	_
30-19	5095-5101	breath	abstract[268]|substance[269]|abstract|abstract[273]	new[268]|new[269]|giv|new[273]	coref|coref	32-7[291_273]|32-7[291_273]
30-20	5102-5109	ethanol	abstract[268]|substance[269]|substance|abstract[273]	new[268]|new[269]|giv|new[273]	coref	32-13[292_0]
30-21	5110-5118	increase	abstract[268]|substance[269]|abstract[273]	new[268]|new[269]|new[273]	_	_
30-22	5119-5121	is	_	_	_	_
30-23	5122-5125	due	_	_	_	_
30-24	5126-5128	to	_	_	_	_
30-25	5129-5132	the	event[274]	giv[274]	coref	31-2[279_274]
30-26	5133-5139	intake	event[274]	giv[274]	_	_
30-27	5140-5144	with	event[274]	giv[274]	_	_
30-28	5145-5155	subsequent	event[274]|substance[275]	giv[274]|new[275]	_	_
30-29	5156-5165	digestion	event[274]|substance[275]	giv[274]|new[275]	_	_
30-30	5166-5168	of	event[274]|substance[275]	giv[274]|new[275]	_	_
30-31	5169-5182	carbohydrates	event[274]|substance[275]|substance	giv[274]|new[275]|giv	_	_
30-32	5183-5186	and	event[274]|substance[275]	giv[274]|new[275]	_	_
30-33	5187-5190	the	event[274]|substance[275]|object[277]	giv[274]|new[275]|new[277]	coref	31-25[285_277]
30-34	5191-5201	intestinal	event[274]|substance[275]|object[277]	giv[274]|new[275]|new[277]	_	_
30-35	5202-5212	microbiota	event[274]|substance[275]|object[277]	giv[274]|new[275]|new[277]	_	_
30-36	5213-5214	.	_	_	_	_

#Text=While the carbohydrate intake at lunch was quite similar in both groups , postprandial hyperglycemia was not and even subtle differences with respect to the intestinal microbiota between T1DM patients and controls have to be considered .
31-1	5215-5220	While	_	_	_	_
31-2	5221-5224	the	event[279]	giv[279]	_	_
31-3	5225-5237	carbohydrate	substance|event[279]	new|giv[279]	_	_
31-4	5238-5244	intake	event[279]	giv[279]	_	_
31-5	5245-5247	at	event[279]	giv[279]	_	_
31-6	5248-5253	lunch	event[279]|event	giv[279]|giv	_	_
31-7	5254-5257	was	_	_	_	_
31-8	5258-5263	quite	_	_	_	_
31-9	5264-5271	similar	_	_	_	_
31-10	5272-5274	in	_	_	_	_
31-11	5275-5279	both	person[281]	new[281]	_	_
31-12	5280-5286	groups	person[281]	new[281]	_	_
31-13	5287-5288	,	_	_	_	_
31-14	5289-5301	postprandial	abstract[282]	giv[282]	_	_
31-15	5302-5315	hyperglycemia	abstract[282]	giv[282]	_	_
31-16	5316-5319	was	_	_	_	_
31-17	5320-5323	not	_	_	_	_
31-18	5324-5327	and	_	_	_	_
31-19	5328-5332	even	abstract[283]	new[283]	_	_
31-20	5333-5339	subtle	abstract[283]	new[283]	_	_
31-21	5340-5351	differences	abstract[283]	new[283]	_	_
31-22	5352-5356	with	abstract[283]	new[283]	_	_
31-23	5357-5364	respect	abstract[283]|abstract[284]	new[283]|giv[284]	ana	32-3[0_284]
31-24	5365-5367	to	abstract[283]|abstract[284]	new[283]|giv[284]	_	_
31-25	5368-5371	the	abstract[283]|abstract[284]|object[285]	new[283]|giv[284]|giv[285]	_	_
31-26	5372-5382	intestinal	abstract[283]|abstract[284]|object[285]	new[283]|giv[284]|giv[285]	_	_
31-27	5383-5393	microbiota	abstract[283]|abstract[284]|object[285]	new[283]|giv[284]|giv[285]	_	_
31-28	5394-5401	between	abstract[283]|abstract[284]|object[285]	new[283]|giv[284]|giv[285]	_	_
31-29	5402-5406	T1DM	abstract[283]|abstract[284]|object[285]|abstract|person[287]|abstract[288]	new[283]|giv[284]|giv[285]|giv|giv[287]|giv[288]	coref|coref|coref|coref|coref|coref	32-21|32-21[295_287]|32-21|32-21[295_287]|32-21|32-21[295_287]
31-30	5407-5415	patients	abstract[283]|abstract[284]|object[285]|person[287]|abstract[288]	new[283]|giv[284]|giv[285]|giv[287]|giv[288]	_	_
31-31	5416-5419	and	abstract[283]|abstract[284]|object[285]|abstract[288]	new[283]|giv[284]|giv[285]|giv[288]	_	_
31-32	5420-5428	controls	abstract[283]|abstract[284]|object[285]|abstract[288]|event	new[283]|giv[284]|giv[285]|giv[288]|giv	_	_
31-33	5429-5433	have	_	_	_	_
31-34	5434-5436	to	_	_	_	_
31-35	5437-5439	be	_	_	_	_
31-36	5440-5450	considered	_	_	_	_
31-37	5451-5452	.	_	_	_	_

#Text=Altogether , this may have caused a slightly more pronounced increase of postprandial ethanol with higher peak ethanol concentrations in T1DM patients .
32-1	5453-5463	Altogether	_	_	_	_
32-2	5464-5465	,	_	_	_	_
32-3	5466-5470	this	abstract	giv	_	_
32-4	5471-5474	may	_	_	_	_
32-5	5475-5479	have	_	_	_	_
32-6	5480-5486	caused	_	_	_	_
32-7	5487-5488	a	abstract[291]	giv[291]	_	_
32-8	5489-5497	slightly	abstract[291]	giv[291]	_	_
32-9	5498-5502	more	abstract[291]	giv[291]	_	_
32-10	5503-5513	pronounced	abstract[291]	giv[291]	_	_
32-11	5514-5522	increase	abstract[291]	giv[291]	_	_
32-12	5523-5525	of	abstract[291]	giv[291]	_	_
32-13	5526-5538	postprandial	abstract[291]|substance[292]	giv[291]|giv[292]	coref	33-1[296_292]
32-14	5539-5546	ethanol	abstract[291]|substance[292]	giv[291]|giv[292]	_	_
32-15	5547-5551	with	abstract[291]|substance[292]	giv[291]|giv[292]	_	_
32-16	5552-5558	higher	abstract[291]|substance[292]|animal[293]	giv[291]|giv[292]|giv[293]	_	_
32-17	5559-5563	peak	abstract[291]|substance[292]|animal[293]	giv[291]|giv[292]|giv[293]	_	_
32-18	5564-5571	ethanol	abstract[291]|substance[292]|animal[293]	giv[291]|giv[292]|giv[293]	_	_
32-19	5572-5586	concentrations	abstract[291]|substance[292]|animal[293]	giv[291]|giv[292]|giv[293]	_	_
32-20	5587-5589	in	abstract[291]|substance[292]|animal[293]	giv[291]|giv[292]|giv[293]	_	_
32-21	5590-5594	T1DM	abstract[291]|substance[292]|animal[293]|abstract|person[295]	giv[291]|giv[292]|giv[293]|giv|giv[295]	coref|coref	33-10[297_295]|33-10[297_295]
32-22	5595-5603	patients	abstract[291]|substance[292]|animal[293]|person[295]	giv[291]|giv[292]|giv[293]|giv[295]	_	_
32-23	5604-5605	.	_	_	_	_

#Text=Elevated endogenous ethanol was also already previously detected in diabetic patients .
33-1	5606-5614	Elevated	substance[296]	giv[296]	_	_
33-2	5615-5625	endogenous	substance[296]	giv[296]	_	_
33-3	5626-5633	ethanol	substance[296]	giv[296]	_	_
33-4	5634-5637	was	_	_	_	_
33-5	5638-5642	also	_	_	_	_
33-6	5643-5650	already	_	_	_	_
33-7	5651-5661	previously	_	_	_	_
33-8	5662-5670	detected	_	_	_	_
33-9	5671-5673	in	_	_	_	_
33-10	5674-5682	diabetic	person[297]	giv[297]	_	_
33-11	5683-5691	patients	person[297]	giv[297]	_	_
33-12	5692-5693	.	_	_	_	_
